196 related articles for article (PubMed ID: 12929322)
1. [Does red-green destroy phytotherapy?].
Krankenpfl J; 2003; 41(4-6):111. PubMed ID: 12929322
[No Abstract] [Full Text] [Related]
2. [The physician caught between two chairs. Comments on the difficulty in dealing with off-label use].
Harder Yv
Urologe A; 2007 Oct; 46(10):1429-34. PubMed ID: 17786403
[No Abstract] [Full Text] [Related]
3. [Open letter to minister of health. Toad medicine].
Erdmann E
Krankenpfl J; 2003; 41(4-6):110-1. PubMed ID: 12929321
[No Abstract] [Full Text] [Related]
4. [Off-label use in psychopharmacotherapy. Letter to Federal Minister Ulla Schmidt, Pulheim, 22 January 2003].
Fritze J
Nervenarzt; 2003 Apr; 74(4):389; discussion 390. PubMed ID: 12800838
[No Abstract] [Full Text] [Related]
5. [Vascular specialists in a campaign against positive list. Threat of deficient care for 4.5 million vascular patients].
Krankenpfl J; 2003; 41(4-6):120. PubMed ID: 12929329
[No Abstract] [Full Text] [Related]
6. [Cannabis in medicine. Legal aspects].
Wartensleben H
Schmerz; 2004 Dec; 18 Suppl 2():S34-5. PubMed ID: 23570089
[No Abstract] [Full Text] [Related]
7. [Cannabis as a medicine": necessary and long overdue?].
Göbel H
Schmerz; 2004 Dec; 18 Suppl 2():S2-3. PubMed ID: 23570081
[No Abstract] [Full Text] [Related]
8. [Legal boundaries of negative and positive lists].
Arndt M
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):630-2. PubMed ID: 9527457
[TBL] [Abstract][Full Text] [Related]
9. [An end to scurrilous recommendations on the new regulation. What is still allowed on the insurance form?].
Schmidt K
MMW Fortschr Med; 2004 Apr; 146(15):60-2. PubMed ID: 15373023
[No Abstract] [Full Text] [Related]
10. [Family physicians resist high prescription risk].
Schmidt K
MMW Fortschr Med; 2003 May; 145(20):58. PubMed ID: 12822233
[No Abstract] [Full Text] [Related]
11. [Positive list of drugs and osteoporosis].
Krankenpfl J; 2003; 41(4-6):113. PubMed ID: 12929324
[No Abstract] [Full Text] [Related]
12. [Legal dispute about the black drug list. Irrespective of positive or negative list--I am in favor].
Thöns M
MMW Fortschr Med; 2006 Oct; 148(40):8. PubMed ID: 17338085
[No Abstract] [Full Text] [Related]
13. [The rheumatologist's conflict between "off-label" prescription and failure to render assistance].
Hellmich B; Gross WL
Z Rheumatol; 2003 Feb; 62(1):34-5. PubMed ID: 12624800
[No Abstract] [Full Text] [Related]
14. [Negative would be welcome. The question is whose brain child this is].
Hakimi R
MMW Fortschr Med; 2006 Nov; 148(44):8. PubMed ID: 17632867
[No Abstract] [Full Text] [Related]
15. [New institute for additional drug evaluation. Do we really need another barrier?].
Schmidt K
MMW Fortschr Med; 2003 Jul; 145(29-30):55-6. PubMed ID: 12958781
[No Abstract] [Full Text] [Related]
16. [Off-label use of drugs--the legal framework].
Koyuncu A
Dtsch Med Wochenschr; 2012 Jul; 137(30):1519-23. PubMed ID: 22869512
[No Abstract] [Full Text] [Related]
17. [Limited prescribing freedom by federal cost regulation?].
Lasek R
Z Arztl Fortbild Qualitatssich; 1997 Nov; 91(7):633-5. PubMed ID: 9527458
[TBL] [Abstract][Full Text] [Related]
18. [In moderate depression. St. John's wort maintains effectiveness].
MMW Fortschr Med; 2004 Aug; 146(31-32):54. PubMed ID: 15529721
[No Abstract] [Full Text] [Related]
19. Economic evaluation for pharmaceuticals in Germany.
Jönsson B
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
[No Abstract] [Full Text] [Related]
20. [Prescribing fictitiously approved drugs: regress threatens!].
Walbert H
MMW Fortschr Med; 2012 Apr; 154(6):10. PubMed ID: 22642016
[No Abstract] [Full Text] [Related]
[Next] [New Search]
